GM-CSF Did Not Allow Doxorubicin Dose Escalation in the MAID Regimen: A Phase I Trial. A Southwest Oncology Group Study

References

• Antman K., Crowley J., Balcerzak S. P., et al. An intergroup Phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soil tissue and bone sarcomas. J Clin Oncol 1993; 11: 1276–1285
   PubMed Web of Science ®Google Scholar
• Antman K., Griffin J. D., Elias A., et al. Effect of recombinant human granulocyte‐macrophage colony stimulation factor on chemotherapy induced myelosuppression. N Engl J Med 1988; 319: 593–598
   PubMed Web of Science ®Google Scholar
• Nemunaitis J., Singer J. W., Buckner D., et al. Use of recombinant human granulocyte‐macrophage colony stimulating factor in autologous marrow transplantation. Blood 1988; 72: 834–836
   PubMed Web of Science ®Google Scholar
• Gulati S., Bennett. Granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) as adjunct therapy in relapsed Hodgkin disease. Ann Intern Med 1992; 116: 177–190
   PubMed Web of Science ®Google Scholar
• Brandt S. J., Peters W. P., Atwater S. K., et al. Effect of recombinant human granulocyte‐macrophage colony‐stimulating factor on hematopoietic reconslilution after high‐dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 1988; 318: 869–876
   PubMed Web of Science ®Google Scholar
• Vadhan‐Raj S., Broxmeyer H., Hittleman W., et al. Abrogating chemotherapy induced myelosuppression by recombinant granulocyte‐macrophage colony‐stimulating factor in patients with sarcoma: Protection at progenitor cell level. J Clin Oncol 1992; 10: 1266–1277
   PubMed Web of Science ®Google Scholar
• Burdach S., Peters C., Paulussen M., et al. Improved relapse free survival in patients with poor prognosis Ewing's sarcoma after consolidation with hyperfractionated total body irradiation and fractionated high dose melphalan followed by high dose etoposide and hematopoietic rescue. Bone Marrow Transplant 1991; 7: 95
   PubMedGoogle Scholar
• de Vries E., Biesma B., Mulder N., et al. A double‐bind placebo‐controlled study with granulocyte‐macrophage colony‐stimulating factor during chemotherapy for ovarian carcinoma. Cancer Res 1991; 51: 116–122
   PubMed Web of Science ®Google Scholar
• Morstyn G., Sheridan W., Lieschke G., . Towards improved cancer therapy using subcutaneously administered hemopoietic colony stimulating factors. Effects of Therapy on Biology and Kinetics of the Residual Tumor, Part B: Clinical Aspects, J. Rogaz, et al. Wiley‐Liss, New York 1990; 29–36
   Google Scholar
• Anderson H., Gurney H., Thatcher N., et al. Recombinant human GM‐CSF in small cell lung cancer: A phase I/II study. Recent Results Cancer Res 1991; 121: 155–161
   PubMedGoogle Scholar
• Jost L. M., Pichert G., Stahel R. A. Placebo controlled phase I/II study of subcutaneous GM‐CSF in patients with germ cell tumors undergoing chemotherapy. Ann Oncol 1990; 1: 439–442
   PubMed Web of Science ®Google Scholar
• Logothetis S. C. J., Dexus F. H., Sella A., et al. Escalated therapy for refractory urothelial tumor: Metholrexate‐vinblastine‐doxorubicin‐cisplatin plus unglycosylated recombinant human granulocyte‐macrophage colony‐stimulating factor. J Natl Cancer Inst 1990; 82: 667–672
   PubMed Web of Science ®Google Scholar
• Aglietta M., Piacibello W., Sanavio F., et al. Kinetics of human hemopoietic cells following in vivo administration of GM‐CSF. J Clin Invest 1989; 83(2)551–557
   PubMedGoogle Scholar
• Schmid L., Thurlimann B., Muller M., et al. Recombinant human granulocyte‐macrophage colony‐stimulating factor for the intensification of cytostatic treatment in advanced cancer. Recent Results Cancer Res 1991; 121: 173–181
   PubMedGoogle Scholar
• Ardizzoni A., Sertoli M. R., Corcione A., et al. Accelerated chemotherapy with or without GM‐CSF for small cell lung cancer: A non‐randomized pilot study. Eur J Cancer 1990; 26: 937–941
   PubMed Web of Science ®Google Scholar
• Walsh C., Blum R., Oratz R., et al. Phase I study of doxorubicin, ICRF‐187 and granulocyte/macrophage‐colony‐stimulating factor. J Cancer Res Clin Oncol 1992; 118: 61–66
   PubMed Web of Science ®Google Scholar
• Hoekman K., Wagstaff J., van Groeningen C. J., et al. Effects of recombinant human granulocyte‐macrophage colony‐stimulating factor on myelosuppression induced by multiple cycles of high dose chemotherapy in patients with advanced breast cancer. J Natl Cancer Inst 1991; 83: 1546–1553
   PubMed Web of Science ®Google Scholar
• Schoenfeld D., Rosenbaum C., Horton J., et al. A comparison of Adriamycin versus vincristine and Adriamycin and cyclophosphamide for advanced sarcoma. Cancer 1982; 50: 2757–2762
   PubMed Web of Science ®Google Scholar
• O'Bryan R. M., Baker L. H., Gottleib J. E., et al. Dose response evaluation of Adriamycin in human neoplasia. Cancer 1977; 39: 1940–1948
   PubMed Web of Science ®Google Scholar
• O'Bryan R. M., Luce J. K., Talley R. W., et al. Phase II evaluation of adriamycin in human neoplasia. Cancer 1973; 32: 1–8
   PubMed Web of Science ®Google Scholar
• Pinedo H. M., Bramwell V. H. C., et al. CYVADIC in advanced soft tissue sarcoma: A randomized study comparing two schedules: A study of the EORTC soft tissue and bone sarcoma group. Cancer 1984; 53: 1825–1831
   PubMed Web of Science ®Google Scholar
• Bodey G. P., Rodriguez V., Murphy W. K., et al. Protected environment‐prophylactic antibiotic program for malignant sarcoma: Randomized trial during remission induction chemotherapy. Cancer 1981; 47: 2422–2429
   PubMed Web of Science ®Google Scholar
• Lerner H., Amato D., Stevens C., et al. Leiomyosarcoma: The Eastern Cooperative Oncology Group experience with 222 patients. Proc Am Assoc Cancer Res 1983; 24: 142, (abstract)
   Web of Science ®Google Scholar
• Bordon E. C., Amato D. A., Rosenbasum C., et al. Randomized comparison of three Adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 1987; 5: 840–850
   PubMed Web of Science ®Google Scholar
• Benjaman R. S., Gottlieb J. A., Baker L. W., et al. Cyvadic vs Cyvadact‐A randomized trial of cyclophosphamide (CY), vincristine (V), and Adriamycin (A), plus dacarbazine (DIC), or actinomycin‐D (DACT in metastatic sarcomas. Proc Am Assoc Cancer Res 1976; 17: 256, (abstract)
   Web of Science ®Google Scholar
• Recent concepts in sarcoma treatment. Chemotherapy of Advanced Sarcomas, K. Antman, J. R. Ryan, L. O. Baker. Kluwer Academic Publishing, Boston 1987; 174–182
   Google Scholar
• Chawla S. P., Rosen G., Lowenbraun S., et al. Role of high dose ifosfamide (HDI) in recurrent osteosarcoma. Proc Am Soc Clin Oncol 1990; 9: 310, (abstract)
   Google Scholar
• Steward W. P., Verweij J., Somers R., et al. The use of recombinant human granulocyte‐macrophage colony‐stimulating factor with combination chemotherapy in the treatment of advanced adult soft‐tissue sarcoma: Early results from the EORTAC soft tissue and bone sarcoma group. Cancer Chemother Pharmacol 1993; 31(Suppl 12)5241–5245
   Google Scholar
• Steward W. P., Verweij J., Somers R., et al. Granulocyte‐macrophage colony stimulating factor allows safe escalation of dose‐intensity of chemotherapy in metastatic adult soft tissue sarcomas: A Study of the European Organization for Research and Treatment of Cancer soft‐tissue and bone sarcoma group. J Clin Oncol 1993; 11(1)15–21
   PubMed Web of Science ®Google Scholar